Trial · NCT06619600
Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction
NCT06619600, Phase 3, Unknown, Hospital Clinic of Barcelona
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction. Trials, record NCT06619600. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06619600
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial Infarction
- NCT number
- NCT06619600
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 54 participants, actual
- Lead sponsor
- Hospital Clinic of Barcelona
- Conditions
- ST-segment Elevation Myocardial Infarction (STEMI), Diabetes Mellitus, Heart Failure, Myocardial Fibrosis
- Interventions
- Dapagliflozin, Placebo
- First posted
- 2024-10-01
- Last updated
- 2025-02-19
- Other registries' IDs
- eudract:2018-003105-25
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Extracellular volume (ECV, %) | 6 months | To determine the effect of dapagliflozin compared with placebo in the change (Δ) of the extracellular volume (ECV) of the remote myocardium between the 6-month and baseline follow- up, evaluated by cardiac magnetic resonance (ΔECV dapagliflozin group versus ΔECV placebo group; \[ΔECV = ECV 6-month - ECV baseline\]). |
| Secondary | Serum levels of C-terminal propeptide of type I procollagen (PICP) | 6 months | To determine the effect of dapagliflozin compared with placebo in the change (Δ) of the serum levels of C-terminal propeptide of type I procollagen (PICP) between the 6-month and baseline follow- up (ΔPICP dapagliflozin group versus ΔPICP placebo group; \[ΔPICP = PICP 6-month - PICP baseline\]). |
| Secondary | N-terminal propeptide of type III (PIIINP) | 6 months | To determine the effect of dapagliflozin compared with placebo in the change (Δ) of the serum levels of N-terminal propeptide of type III (PIIINP) between the 6-month and baseline follow- up (ΔPIIINP dapagliflozin group versus ΔPIIINP placebo group; \[ΔPIIINP = PIIINP 6-month - PIIINP baseline\]). |
| Secondary | Galectin-3 procollagen (Gal-3) | 6 months | To determine the effect of dapagliflozin compared with placebo in the change (Δ) of the serum levels of galectin-3 procollagen (Gal-3) between the 6-month and baseline follow- up (ΔGal-3 dapagliflozin group versus ΔGal-3 placebo group; \[ΔGal-3 = Gal-3 6-month - Gal-3 baseline\]). |
| Secondary | High-Sensitivity cardiac Troponin I (hs-cTnI) | 6 months | To determine the effect of dapagliflozin compared with placebo in the change (Δ) of the serum levels of High-Sensitivity cardiac Troponin I (hs-cTnI) between the 6-month and baseline follow- up (hs-cTnI dapagliflozin group versus hs-cTnI placebo group; \[Δhs-cTnI = hs-cTnI 6-month - hs-cTnI baseline\]). |
| Other | N-terminal pro-brain natriuretic peptide (NT-proBNP) | 6 months | To determine the effect of dapagliflozin compared with placebo in the change (Δ) of the serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) between the 6-month and baseline follow- up (NT-proBNP dapagliflozin group versus NT-proBNP placebo group; \[ΔNT-proBNP = NT-proBNP 6-month - NT-proBNP baseline\]). |
| Other | Soluble suppression of tumorigenicity 2 (sST2) | 6 months | To determine the effect of dapagliflozin compared with placebo in the change (Δ) of the serum levels of Soluble suppression of tumorigenicity 2 (sST2) between the 6-month and baseline follow- up (sST2 dapagliflozin group versus sST2 placebo group; \[ΔsST2 = sST2 6-month - sST2 baseline\]). |
| Other | Indexed ventricular mass of the left ventricle (LVMI, g/m^2) | 6 months | To determine the effect of dapagliflozin compared with placebo in the change (Δ) of the Indexed ventricular mass of the left ventricle (LVMI) between the 6-month and baseline follow- up, evaluated by cardiac magnetic resonance (ΔLVMI dapagliflozin group versus ΔLVMI placebo group; \[ΔLVMI = LVMI 6-month - LVMI baseline\]). |
| Other | Indexed End-diastolic volume of the left ventricle (LVEDVI, mL/m^2) | 6 months | To determine the effect of dapagliflozin compared with placebo in the change (Δ) of the Indexed End-diastolic volume of the left ventricle (LVEDVI) between the 6-month and baseline follow- up, evaluated by cardiac magnetic resonance (ΔLVEDVI dapagliflozin group versus ΔLVEDVI placebo group; \[ΔLVEDVI = LVEDVI 6-month - LVEDVI baseline\]). |
| Other | Indexed End-systolic volume of the left ventricle (LVESVI, mL/m^2) | 6 months | To determine the effect of dapagliflozin compared with placebo in the change (Δ) of the Indexed End-systolic volume of the left ventricle (LVESVI) between the 6-month and baseline follow- up, evaluated by cardiac magnetic resonance (ΔLVESVI dapagliflozin group versus ΔLVESVI placebo group; \[ΔLVESVI = LVESVI 6-month - LVESVI baseline\]). |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06619600
GET https://conductscience.org/api/trials/v1/NCT06619600/registered